- 精华
- 0
- 积分
- 1300
- 经验
- 1300 点
- 威望
- 129 点
- 金钱
- 129 ¥
- 魅力
- 129
|
OG CR 113 求助!!
The pharmaceutical industry argues that because new
drugs will not be developed unless heavy development
costs can be recouped in later sales, the current
20 years of protection provided by patents should
be extended in the case of newly developed drugs.
However, in other industries new-product development
continues despite high development costs, a fact that
indicates that the extension is unnecessary.
Which of the following, if true, most strongly supports
the pharmaceutical industry’s argument against the
challenge made above?
(A) No industries other than the pharmaceutical
industry have asked for an extension of the
20-year limit on patent protection.
(B) Clinical trials of new drugs, which occur after
the patent is granted and before the new drug
can be marketed, often now take as long as
10 years to complete.
(C) There are several industries in which the ratio of
research and development costs to revenues is
higher than it is in the pharmaceutical industry.
(D) An existing patent for a drug does not legally
prevent pharmaceutical companies from
bringing to market alternative drugs, provided
they are sufficiently dissimilar to the patented
drug.
(E) Much recent industrial innovation has occurred
in products—for example, in the computer and
electronics industries—for which patent
protection is often very ineffective.
题目不是问支持 pharmaceutical industry argument 要 extend保护时间么?
为什么选B呢?B说只要十年时间不是weaken了么? |
|